Beyond mea_老虎社区_美港股上老虎

Shlee
2021-12-10

Beyond meat

3 High-Growth Stocks That Are Screaming Buys in December<blockquote>12月值得买入的3只高增长股票</blockquote>

Now is a good time to be greedy and buy up these depressed stocks.

3 High-Growth Stocks That Are Screaming Buys in December<blockquote>12月值得买入的3只高增长股票</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":605616949,"tweetId":"605616949","gmtCreate":1639151363801,"gmtModify":1639151363866,"author":{"id":3573647345754035,"idStr":"3573647345754035","authorId":3573647345754035,"authorIdStr":"3573647345754035","name":"Shlee","avatar":"https://static.tigerbbs.com/4252964386d65759fde597203ee9a21f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Beyond meat</body></html>","htmlText":"<html><head></head><body>Beyond meat</body></html>","text":"Beyond meat","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/605616949","repostId":1147480652,"repostType":2,"repost":{"id":"1147480652","kind":"news","pubTimestamp":1639125342,"share":"https://www.laohu8.com/m/news/1147480652?lang=zh_CN&edition=full","pubTime":"2021-12-10 16:35","market":"us","language":"en","title":"3 High-Growth Stocks That Are Screaming Buys in December<blockquote>12月值得买入的3只高增长股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1147480652","media":"Motley Fool","summary":"Now is a good time to be greedy and buy up these depressed stocks.","content":"If you're looking to do some Christmas shopping on stocks, there are some incredibly good deals out there right now. The market isn't crashing, but some stocks have been struggling of late that you likely won't regret adding to your portfolio today if you're a long-term investor.<blockquote>如果您想在圣诞节购买股票，现在有一些非常划算的交易。市场并没有崩溃，但一些股票最近一直在苦苦挣扎，如果您是长期投资者，您可能不会后悔今天添加到您的投资组合中。</blockquote> Shares of&nbsp;Jazz Pharmaceuticals,DocuSign,and&nbsp;Beyond Meat&nbsp;haven't been this cheap in months. And all these businesses have the potential to generate some strong growth numbers in the months and years ahead, which could mean great returns for you.<blockquote>本公司之股份爵士制药公司,DocuSign，和Beyond Meat几个月没这么便宜了。所有这些业务都有潜力在未来几个月和几年内产生强劲的增长数字，这可能意味着您获得巨大的回报。</blockquote> <img src=\"https://static.tigerbbs.com/2aaa8c5069132f2d41beafbfbef0705f\" tg-width=\"2000\" tg-height=\"1334\" width=\"100%\" height=\"auto\">Image source: Getty Images<blockquote>图片来源：盖蒂图片社</blockquote> 1. Jazz Pharmaceuticals<blockquote>1.爵士制药</blockquote> Healthcare company&nbsp;Jazz Pharmaceuticals is trading around its 52-week low, down 25% year to date even as the&nbsp;S&amp;P 500&nbsp;is up 22%. In February, the company announced it was acquiring GW Pharmaceuticals, which makes Epidiolex, a cannabis-based drug that treats seizures. Softness in the cannabis market (due to a disappointing pace in legalization) may in part be affecting the shares.<blockquote>医疗保健公司Jazz Pharmaceuticals的交易价格接近52周低点，今年迄今已下跌25%，尽管标普500上涨了22%。今年2月，该公司宣布收购GW Pharmaceuticals，该公司生产Epidiolex，一种治疗癫痫发作的大麻药物。大麻市场的疲软（由于合法化步伐令人失望）可能在一定程度上影响了股价。</blockquote> Yet, the company still has promise. Jazz reported its latest quarterly results in November, and revenue rose 39% year over year to $838 million. Over half of that came from products that were either new or just acquired, such as Epidiolex. Its sales rose a robust 21% despite investor concerns.<blockquote>然而，该公司仍然有希望。Jazz于11月公布了最新季度业绩，收入同比增长39%至8.38亿美元。其中一半以上来自新产品或刚刚收购的产品，例如Epidiolex。尽管投资者感到担忧，但其销售额仍强劲增长了21%。</blockquote> In fact, Epidiolex is what makes Jazz a promising buy here as the company is looking at new indications for it; plus, it is rolling out Epidiolex to new countries in Europe. Both moves could bolster the drug's sales over the long term.<blockquote>事实上，Epidiolex使Jazz成为一个有前途的买家，因为该公司正在寻找新的适应症；此外，它还将Epidiolex推广到欧洲的新国家。从长远来看，这两项举措都可能提振该药物的销售。</blockquote> Prospects for long-term profitability also look strong. The company has generated impressive gross margins of 82% or better in each of the past four quarters. Although its bottom line has fallen into the red after the acquisition of GW Pharma, that's not where investors should expect the company to stay. Jazz could be a steal of a deal right now.<blockquote>长期盈利前景看起来也很强劲。该公司在过去四个季度每个季度的毛利率都达到了82%或更高，令人印象深刻。尽管在收购GW Pharma后，其利润已陷入亏损，但这并不是投资者对该公司的预期。爵士乐现在可能是一笔划算的交易。</blockquote> 2. DocuSign<blockquote>2.DocuSign</blockquote> Anytime a stock&nbsp;falls more than 40% in a&nbsp;single day, it's worth asking whether the market overreacted. That's what looks to have happened with DocuSign. The company beat expectations when it reported third-quarter results last week. Sales for the period ended Oct. 31 soared 42% year over year to $545.5 million. The company also regularly boasts a gross profit of close to 80%.<blockquote>每当股票在一年内下跌超过40%时单日，值得追问的是市场是否反应过度。DocuSign似乎就是这样。该公司上周公布第三季度业绩超出预期。截至10月31日的期间销售额同比飙升42%至5.455亿美元。该公司的毛利润也经常接近80%。</blockquote> Yet, that wasn't enough for investors. A sell-off ensued as the tech company provided fourth-quarter revenue guidance of $557 million to $563 million -- and that fell well shy of the $574 million that analysts were expecting. While the estimate is below analysts' figures, that hardly seems to be a reason to warrant such an incredible drop in price.<blockquote>然而，这对投资者来说还不够。随着这家科技公司提供的第四季度收入指引为5.57亿美元至5.63亿美元，远低于分析师预期的5.74亿美元，抛售随之而来。虽然这一估计低于分析师的数据，但这似乎很难成为价格如此令人难以置信的下跌的理由。</blockquote> Unfortunately, in the era of meme stocks, where companies with questionable growth prospects such as&nbsp;AMC Entertainment&nbsp;can skyrocket over 1,000% -- mainly on hype from retail investors -- high-quality businesses like DocuSign can also fall drastically without a good reason. Such a steep sell-off due to one quarter's guidance is the epitome of short-term thinking.<blockquote>不幸的是，在模因股票时代，增长前景值得怀疑的公司，例如AMC院线可以飙升超过1,000%——主要是由于散户投资者的炒作——像DocuSign这样的优质企业也可能在没有充分理由的情况下大幅下跌。由于一个季度的指引而出现如此急剧的抛售，是短期思维的缩影。</blockquote> DocuSign will likely see demand subside a bit as people return to the office and are no longer relying as much on digital signatures. However, that doesn't mean its growth is over. Analysts from Fortune Business Insights project that the global digital signature market will grow at a compound annual rate of 28.9% through 2027.<blockquote>随着人们回到办公室，不再那么依赖数字签名，DocuSign的需求可能会有所下降。然而，这并不意味着它的增长已经结束。Fortune Business Insights分析师预计，到2027年，全球数字签名市场将以28.9%的复合年增长率增长。</blockquote> So despite the bearishness, the sky isn't falling for DocuSign, and it looks like it could be a bargain buy right now. Although the stock has bounced up from the lows it hit last week, it's still around levels not seen since June 2020.<blockquote>因此，尽管存在看跌情绪，但DocuSign的天并没有塌下来，看起来现在可能是一个便宜货。尽管该股已从上周触及的低点反弹，但仍处于2020年6月以来的最高水平附近。</blockquote> 3. Beyond Meat<blockquote>3.Beyond Meat</blockquote> Another stock that has struggled after releasing earnings is Beyond Meat. At just over $70, the stock is trading near its 52-week lows, having fallen 43% this year.It's not a huge surprise given that the company has an unfortunate trend of missing earnings expectations. Yet, Beyond Meat is a great recovery stock to own as economies see a return to normal and COVID-19 no longer impacts demand for its products or disrupts the supply chain.<blockquote>另一只在发布财报后陷入困境的股票是Beyond Meat。该股股价略高于70美元，接近52周低点，今年已下跌43%。鉴于该公司有未达到盈利预期的不幸趋势，这并不令人意外。然而，随着经济恢复正常，COVID-19不再影响对其产品的需求或扰乱供应链，Beyond Meat是一只值得持有的复苏股票。</blockquote> In 2019, the company's sales of $298 million were more than triple the $88 million it reported in 2018. And in 2020, sales rose further to $407 million but at a much lower growth rate of 37%. For the latest quarter ended Oct. 2, net revenue increased just 13% to $106 million -- and in the U.S. market, sales were actually down 14%. It was the company's international operations that kept the overall numbers in the green (rising by an impressive 143%).<blockquote>2019年，该公司的销售额为2.98亿美元，是2018年8800万美元的三倍多。2020年，销售额进一步上升至4.07亿美元，但增长率低得多，为37%。截至10月2日的最新季度，净收入仅增长13%，达到1.06亿美元，而在美国市场，销售额实际上下降了14%。正是该公司的国际业务使整体数字保持绿色（增长了令人印象深刻的143%）。</blockquote> However, the company's performance should improve with a return to normalcy. In addition, Beyond Meat has new products and deals that could propel it to even greater heights than before. It is supplying fast-food giant&nbsp;McDonald's&nbsp;with the patty for its McPlant burger, which could be a boon for the business if it proves to be successful. Plus, it has a joint venture with soft-drink maker&nbsp;PepsiCo&nbsp;to develop new products. Beyond Meat also recently launched meatless chicken tenders.<blockquote>然而，随着恢复正常，该公司的业绩应该会有所改善。此外，Beyond Meat的新产品和交易可能会将其推向比以前更高的高度。它正在供应快餐巨头麦当劳McPlant汉堡的肉饼，如果被证明是成功的，这可能会给企业带来福音。此外，它还与软饮料制造商成立了一家合资企业百事可乐开发新产品。Beyond Meat最近也推出了无肉鸡柳。</blockquote> Things may look grim in the short term for Beyond Meat, but there are many catalysts out there that could make its stock price today look incredibly cheap in a year or two.<blockquote>对于Beyond Meat来说，短期内的情况可能看起来很严峻，但有许多催化剂可能会使其今天的股价在一两年内看起来非常便宜。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 High-Growth Stocks That Are Screaming Buys in December<blockquote>12月值得买入的3只高增长股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 High-Growth Stocks That Are Screaming Buys in December<blockquote>12月值得买入的3只高增长股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-12-10 16:35\n\n</h4>\n</header>\n<article>\nIf you're looking to do some Christmas shopping on stocks, there are some incredibly good deals out there right now. The market isn't crashing, but some stocks have been struggling of late that you likely won't regret adding to your portfolio today if you're a long-term investor.<blockquote>如果您想在圣诞节购买股票，现在有一些非常划算的交易。市场并没有崩溃，但一些股票最近一直在苦苦挣扎，如果您是长期投资者，您可能不会后悔今天添加到您的投资组合中。</blockquote> Shares of&nbsp;Jazz Pharmaceuticals,DocuSign,and&nbsp;Beyond Meat&nbsp;haven't been this cheap in months. And all these businesses have the potential to generate some strong growth numbers in the months and years ahead, which could mean great returns for you.<blockquote>本公司之股份爵士制药公司,DocuSign，和Beyond Meat几个月没这么便宜了。所有这些业务都有潜力在未来几个月和几年内产生强劲的增长数字，这可能意味着您获得巨大的回报。</blockquote> <img src=\"https://static.tigerbbs.com/2aaa8c5069132f2d41beafbfbef0705f\" tg-width=\"2000\" tg-height=\"1334\" width=\"100%\" height=\"auto\">Image source: Getty Images<blockquote>图片来源：盖蒂图片社</blockquote> 1. Jazz Pharmaceuticals<blockquote>1.爵士制药</blockquote> Healthcare company&nbsp;Jazz Pharmaceuticals is trading around its 52-week low, down 25% year to date even as the&nbsp;S&amp;P 500&nbsp;is up 22%. In February, the company announced it was acquiring GW Pharmaceuticals, which makes Epidiolex, a cannabis-based drug that treats seizures. Softness in the cannabis market (due to a disappointing pace in legalization) may in part be affecting the shares.<blockquote>医疗保健公司Jazz Pharmaceuticals的交易价格接近52周低点，今年迄今已下跌25%，尽管标普500上涨了22%。今年2月，该公司宣布收购GW Pharmaceuticals，该公司生产Epidiolex，一种治疗癫痫发作的大麻药物。大麻市场的疲软（由于合法化步伐令人失望）可能在一定程度上影响了股价。</blockquote> Yet, the company still has promise. Jazz reported its latest quarterly results in November, and revenue rose 39% year over year to $838 million. Over half of that came from products that were either new or just acquired, such as Epidiolex. Its sales rose a robust 21% despite investor concerns.<blockquote>然而，该公司仍然有希望。Jazz于11月公布了最新季度业绩，收入同比增长39%至8.38亿美元。其中一半以上来自新产品或刚刚收购的产品，例如Epidiolex。尽管投资者感到担忧，但其销售额仍强劲增长了21%。</blockquote> In fact, Epidiolex is what makes Jazz a promising buy here as the company is looking at new indications for it; plus, it is rolling out Epidiolex to new countries in Europe. Both moves could bolster the drug's sales over the long term.<blockquote>事实上，Epidiolex使Jazz成为一个有前途的买家，因为该公司正在寻找新的适应症；此外，它还将Epidiolex推广到欧洲的新国家。从长远来看，这两项举措都可能提振该药物的销售。</blockquote> Prospects for long-term profitability also look strong. The company has generated impressive gross margins of 82% or better in each of the past four quarters. Although its bottom line has fallen into the red after the acquisition of GW Pharma, that's not where investors should expect the company to stay. Jazz could be a steal of a deal right now.<blockquote>长期盈利前景看起来也很强劲。该公司在过去四个季度每个季度的毛利率都达到了82%或更高，令人印象深刻。尽管在收购GW Pharma后，其利润已陷入亏损，但这并不是投资者对该公司的预期。爵士乐现在可能是一笔划算的交易。</blockquote> 2. DocuSign<blockquote>2.DocuSign</blockquote> Anytime a stock&nbsp;falls more than 40% in a&nbsp;single day, it's worth asking whether the market overreacted. That's what looks to have happened with DocuSign. The company beat expectations when it reported third-quarter results last week. Sales for the period ended Oct. 31 soared 42% year over year to $545.5 million. The company also regularly boasts a gross profit of close to 80%.<blockquote>每当股票在一年内下跌超过40%时单日，值得追问的是市场是否反应过度。DocuSign似乎就是这样。该公司上周公布第三季度业绩超出预期。截至10月31日的期间销售额同比飙升42%至5.455亿美元。该公司的毛利润也经常接近80%。</blockquote> Yet, that wasn't enough for investors. A sell-off ensued as the tech company provided fourth-quarter revenue guidance of $557 million to $563 million -- and that fell well shy of the $574 million that analysts were expecting. While the estimate is below analysts' figures, that hardly seems to be a reason to warrant such an incredible drop in price.<blockquote>然而，这对投资者来说还不够。随着这家科技公司提供的第四季度收入指引为5.57亿美元至5.63亿美元，远低于分析师预期的5.74亿美元，抛售随之而来。虽然这一估计低于分析师的数据，但这似乎很难成为价格如此令人难以置信的下跌的理由。</blockquote> Unfortunately, in the era of meme stocks, where companies with questionable growth prospects such as&nbsp;AMC Entertainment&nbsp;can skyrocket over 1,000% -- mainly on hype from retail investors -- high-quality businesses like DocuSign can also fall drastically without a good reason. Such a steep sell-off due to one quarter's guidance is the epitome of short-term thinking.<blockquote>不幸的是，在模因股票时代，增长前景值得怀疑的公司，例如AMC院线可以飙升超过1,000%——主要是由于散户投资者的炒作——像DocuSign这样的优质企业也可能在没有充分理由的情况下大幅下跌。由于一个季度的指引而出现如此急剧的抛售，是短期思维的缩影。</blockquote> DocuSign will likely see demand subside a bit as people return to the office and are no longer relying as much on digital signatures. However, that doesn't mean its growth is over. Analysts from Fortune Business Insights project that the global digital signature market will grow at a compound annual rate of 28.9% through 2027.<blockquote>随着人们回到办公室，不再那么依赖数字签名，DocuSign的需求可能会有所下降。然而，这并不意味着它的增长已经结束。Fortune Business Insights分析师预计，到2027年，全球数字签名市场将以28.9%的复合年增长率增长。</blockquote> So despite the bearishness, the sky isn't falling for DocuSign, and it looks like it could be a bargain buy right now. Although the stock has bounced up from the lows it hit last week, it's still around levels not seen since June 2020.<blockquote>因此，尽管存在看跌情绪，但DocuSign的天并没有塌下来，看起来现在可能是一个便宜货。尽管该股已从上周触及的低点反弹，但仍处于2020年6月以来的最高水平附近。</blockquote> 3. Beyond Meat<blockquote>3.Beyond Meat</blockquote> Another stock that has struggled after releasing earnings is Beyond Meat. At just over $70, the stock is trading near its 52-week lows, having fallen 43% this year.It's not a huge surprise given that the company has an unfortunate trend of missing earnings expectations. Yet, Beyond Meat is a great recovery stock to own as economies see a return to normal and COVID-19 no longer impacts demand for its products or disrupts the supply chain.<blockquote>另一只在发布财报后陷入困境的股票是Beyond Meat。该股股价略高于70美元，接近52周低点，今年已下跌43%。鉴于该公司有未达到盈利预期的不幸趋势，这并不令人意外。然而，随着经济恢复正常，COVID-19不再影响对其产品的需求或扰乱供应链，Beyond Meat是一只值得持有的复苏股票。</blockquote> In 2019, the company's sales of $298 million were more than triple the $88 million it reported in 2018. And in 2020, sales rose further to $407 million but at a much lower growth rate of 37%. For the latest quarter ended Oct. 2, net revenue increased just 13% to $106 million -- and in the U.S. market, sales were actually down 14%. It was the company's international operations that kept the overall numbers in the green (rising by an impressive 143%).<blockquote>2019年，该公司的销售额为2.98亿美元，是2018年8800万美元的三倍多。2020年，销售额进一步上升至4.07亿美元，但增长率低得多，为37%。截至10月2日的最新季度，净收入仅增长13%，达到1.06亿美元，而在美国市场，销售额实际上下降了14%。正是该公司的国际业务使整体数字保持绿色（增长了令人印象深刻的143%）。</blockquote> However, the company's performance should improve with a return to normalcy. In addition, Beyond Meat has new products and deals that could propel it to even greater heights than before. It is supplying fast-food giant&nbsp;McDonald's&nbsp;with the patty for its McPlant burger, which could be a boon for the business if it proves to be successful. Plus, it has a joint venture with soft-drink maker&nbsp;PepsiCo&nbsp;to develop new products. Beyond Meat also recently launched meatless chicken tenders.<blockquote>然而，随着恢复正常，该公司的业绩应该会有所改善。此外，Beyond Meat的新产品和交易可能会将其推向比以前更高的高度。它正在供应快餐巨头麦当劳McPlant汉堡的肉饼，如果被证明是成功的，这可能会给企业带来福音。此外，它还与软饮料制造商成立了一家合资企业百事可乐开发新产品。Beyond Meat最近也推出了无肉鸡柳。</blockquote> Things may look grim in the short term for Beyond Meat, but there are many catalysts out there that could make its stock price today look incredibly cheap in a year or two.<blockquote>对于Beyond Meat来说，短期内的情况可能看起来很严峻，但有许多催化剂可能会使其今天的股价在一两年内看起来非常便宜。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/12/09/3-high-growth-stocks-that-are-screaming-buys-in-de/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","DOCU":"Docusign","JAZZ":"爵士制药"},"source_url":"https://www.fool.com/investing/2021/12/09/3-high-growth-stocks-that-are-screaming-buys-in-de/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147480652","content_text":"If you're looking to do some Christmas shopping on stocks, there are some incredibly good deals out there right now. The market isn't crashing, but some stocks have been struggling of late that you likely won't regret adding to your portfolio today if you're a long-term investor.\nShares of Jazz Pharmaceuticals,DocuSign,and Beyond Meat haven't been this cheap in months. And all these businesses have the potential to generate some strong growth numbers in the months and years ahead, which could mean great returns for you.\nImage source: Getty Images\n1. Jazz Pharmaceuticals\nHealthcare company Jazz Pharmaceuticals is trading around its 52-week low, down 25% year to date even as the S&P 500 is up 22%. In February, the company announced it was acquiring GW Pharmaceuticals, which makes Epidiolex, a cannabis-based drug that treats seizures. Softness in the cannabis market (due to a disappointing pace in legalization) may in part be affecting the shares.\nYet, the company still has promise. Jazz reported its latest quarterly results in November, and revenue rose 39% year over year to $838 million. Over half of that came from products that were either new or just acquired, such as Epidiolex. Its sales rose a robust 21% despite investor concerns.\nIn fact, Epidiolex is what makes Jazz a promising buy here as the company is looking at new indications for it; plus, it is rolling out Epidiolex to new countries in Europe. Both moves could bolster the drug's sales over the long term.\nProspects for long-term profitability also look strong. The company has generated impressive gross margins of 82% or better in each of the past four quarters. Although its bottom line has fallen into the red after the acquisition of GW Pharma, that's not where investors should expect the company to stay. Jazz could be a steal of a deal right now.\n2. DocuSign\nAnytime a stock falls more than 40% in a single day, it's worth asking whether the market overreacted. That's what looks to have happened with DocuSign. The company beat expectations when it reported third-quarter results last week. Sales for the period ended Oct. 31 soared 42% year over year to $545.5 million. The company also regularly boasts a gross profit of close to 80%.\nYet, that wasn't enough for investors. A sell-off ensued as the tech company provided fourth-quarter revenue guidance of $557 million to $563 million -- and that fell well shy of the $574 million that analysts were expecting. While the estimate is below analysts' figures, that hardly seems to be a reason to warrant such an incredible drop in price.\nUnfortunately, in the era of meme stocks, where companies with questionable growth prospects such as AMC Entertainment can skyrocket over 1,000% -- mainly on hype from retail investors -- high-quality businesses like DocuSign can also fall drastically without a good reason. Such a steep sell-off due to one quarter's guidance is the epitome of short-term thinking.\nDocuSign will likely see demand subside a bit as people return to the office and are no longer relying as much on digital signatures. However, that doesn't mean its growth is over. Analysts from Fortune Business Insights project that the global digital signature market will grow at a compound annual rate of 28.9% through 2027.\nSo despite the bearishness, the sky isn't falling for DocuSign, and it looks like it could be a bargain buy right now. Although the stock has bounced up from the lows it hit last week, it's still around levels not seen since June 2020.\n3. Beyond Meat\nAnother stock that has struggled after releasing earnings is Beyond Meat. At just over $70, the stock is trading near its 52-week lows, having fallen 43% this year.It's not a huge surprise given that the company has an unfortunate trend of missing earnings expectations. Yet, Beyond Meat is a great recovery stock to own as economies see a return to normal and COVID-19 no longer impacts demand for its products or disrupts the supply chain.\nIn 2019, the company's sales of $298 million were more than triple the $88 million it reported in 2018. And in 2020, sales rose further to $407 million but at a much lower growth rate of 37%. For the latest quarter ended Oct. 2, net revenue increased just 13% to $106 million -- and in the U.S. market, sales were actually down 14%. It was the company's international operations that kept the overall numbers in the green (rising by an impressive 143%).\nHowever, the company's performance should improve with a return to normalcy. In addition, Beyond Meat has new products and deals that could propel it to even greater heights than before. It is supplying fast-food giant McDonald's with the patty for its McPlant burger, which could be a boon for the business if it proves to be successful. Plus, it has a joint venture with soft-drink maker PepsiCo to develop new products. Beyond Meat also recently launched meatless chicken tenders.\nThings may look grim in the short term for Beyond Meat, but there are many catalysts out there that could make its stock price today look incredibly cheap in a year or two.","news_type":1,"symbols_score_info":{"DOCU":0.9,"JAZZ":0.9,"BYND":0.9}},"isVote":1,"tweetType":1,"viewCount":1983,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":10,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}